Full text is available at the source.
Abstract
Glucagon-like peptide-1 agonists are associated with reports of erectile dysfunction in some male patients.
- GLP-1 agonists have significant effects on weight loss and blood sugar management.
- Concerns have emerged about the potential side effect of erectile dysfunction in a subset of users.
- Post-marketing surveillance is highlighting the need for further investigation into this issue.
Simplified